BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu M, Guo F. Recent updates on cancer immunotherapy. Prec Clin Med. 2018;1:65-74. [PMID: 30687562 DOI: 10.1093/pcmedi/pby011] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Roy A, Datta S, Bhatia KS, Bhumika, Jha P, Prasad R. Role of plant derived bioactive compounds against cancer. South African Journal of Botany 2021. [DOI: 10.1016/j.sajb.2021.10.015] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Sfera A, Osorio C, Jafri N, Diaz EL, Campo Maldonado JE. Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis. Front Immunol 2020;11:1472. [PMID: 32655579 DOI: 10.3389/fimmu.2020.01472] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
3 Yang H, Wang K, Wang T, Li M, Li B, Li S, Yuan L. The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer. Front Oncol 2020;10:300. [PMID: 32195194 DOI: 10.3389/fonc.2020.00300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
4 Dyrka K, Witasik D, Czarnywojtek A, Łącka K. The influence of monoclonal antibodies for cancer treatment on the endocrine system. Postepy Hig Med Dosw 2021;75:317-27. [DOI: 10.5604/01.3001.0014.8889] [Reference Citation Analysis]
5 Valdés-Ferrada J, Muñoz-Durango N, Pérez-Sepulveda A, Muñiz S, Coronado-Arrázola I, Acevedo F, Soto JA, Bueno SM, Sánchez C, Kalergis AM. Peripheral Blood Classical Monocytes and Plasma Interleukin 10 Are Associated to Neoadjuvant Chemotherapy Response in Breast Cancer Patients. Front Immunol 2020;11:1413. [PMID: 32733470 DOI: 10.3389/fimmu.2020.01413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yu Y, Zhao Y, Zhou G, Wang X. Therapeutic Efficacy of Delta-Like Ligand 4 Gene Vaccine Overexpression on Liver Cancer in Mice. Technol Cancer Res Treat 2020;19:1533033820942205. [PMID: 33191858 DOI: 10.1177/1533033820942205] [Reference Citation Analysis]
7 Vaidya FU, Sufiyan Chhipa A, Mishra V, Gupta VK, Rawat SG, Kumar A, Pathak C. Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep (Hoboken) 2020;:e1291. [PMID: 33052041 DOI: 10.1002/cnr2.1291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Wang C, Li J, Zhang Q, Wu J, Xiao Y, Song L, Gong H, Li Y. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer. BMC Cancer 2021;21:968. [PMID: 34454455 DOI: 10.1186/s12885-021-08662-2] [Reference Citation Analysis]
9 Lee HH, Kim I, Kim UK, Choi SS, Kim TY, Lee D, Lee Y, Lee J, Jo J, Lee YT, Lee HJ, Kim SJ, Ahn JS. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models. Neoplasia 2021;24:98-108. [PMID: 34954452 DOI: 10.1016/j.neo.2021.12.005] [Reference Citation Analysis]
10 Arcangeli S, Mestermann K, Weber J, Bonini C, Casucci M, Hudecek M. Overcoming key challenges in cancer immunotherapy with engineered T cells. Curr Opin Oncol 2020;32:398-407. [PMID: 32796230 DOI: 10.1097/CCO.0000000000000664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ruan S, Huang Y, He M, Gao H. Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy. Adv Sci (Weinh) 2022;9:e2200027. [PMID: 35343112 DOI: 10.1002/advs.202200027] [Reference Citation Analysis]
12 Joshi A, Tandel N, Tyagi P, Dalai SK, Bisen PS, Tyagi RK. RNA-loaded dendritic cells: more than a tour de force in cancer therapeutics. Immunotherapy 2019;11:1129-47. [PMID: 31390917 DOI: 10.2217/imt-2019-0058] [Reference Citation Analysis]
13 Deligiorgi MV, Panayiotidis MI, Trafalis DT. Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions. Int Immunopharmacol 2019;77:105942. [PMID: 31699669 DOI: 10.1016/j.intimp.2019.105942] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Ayaz F, Demirbag B, Ocakoglu K. Immunoactive photosensitizers had photodynamic immunostimulatory and immunomodulatory effects on mammalian macrophages. Photodiagnosis Photodyn Ther 2020;32:102034. [PMID: 33017658 DOI: 10.1016/j.pdpdt.2020.102034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Dash BS, Jose G, Lu YJ, Chen JP. Functionalized Reduced Graphene Oxide as a Versatile Tool for Cancer Therapy. Int J Mol Sci 2021;22:2989. [PMID: 33804239 DOI: 10.3390/ijms22062989] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
16 Xu W, Lau ZWX, Fulop T, Larbi A. The Aging of γδ T Cells. Cells 2020;9:E1181. [PMID: 32397491 DOI: 10.3390/cells9051181] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
17 Huang Q, Lei Y, Li X, Guo F, Liu M. A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance. Front Cell Dev Biol 2020;8:580140. [PMID: 33344447 DOI: 10.3389/fcell.2020.580140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Focaccetti C, Izzi V, Benvenuto M, Fazi S, Ciuffa S, Giganti MG, Potenza V, Manzari V, Modesti A, Bei R. Polyphenols as Immunomodulatory Compounds in the Tumor Microenvironment: Friends or Foes? Int J Mol Sci 2019;20:E1714. [PMID: 30959898 DOI: 10.3390/ijms20071714] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
19 Farghaly TA, Al-Hasani WA, Abdulwahab HG. An updated patent review of VEGFR-2 inhibitors (2017-present). Expert Opin Ther Pat 2021;:1-19. [PMID: 34043477 DOI: 10.1080/13543776.2021.1935872] [Reference Citation Analysis]
20 Zhang Z, Zeng P, Gao W, Zhou Q, Feng T, Tian X. Circadian clock: a regulator of the immunity in cancer. Cell Commun Signal 2021;19:37. [PMID: 33752691 DOI: 10.1186/s12964-021-00721-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Le I, Dhandayuthapani S, Chacon J, Eiring AM, Gadad SS. Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics. Vaccines 2022;10:816. [DOI: 10.3390/vaccines10050816] [Reference Citation Analysis]
22 Zheng X, Fernando V, Sharma V, Walia Y, Letson J, Furuta S. Correction of arginine metabolism with sepiapterin-the precursor of nitric oxide synthase cofactor BH4-induces immunostimulatory-shift of breast cancer. Biochem Pharmacol 2020;176:113887. [PMID: 32112882 DOI: 10.1016/j.bcp.2020.113887] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
23 Sarasola MP, Táquez Delgado MA, Nicoud MB, Medina VA. Histamine in cancer immunology and immunotherapy. Current status and new perspectives. Pharmacol Res Perspect 2021;9:e00778. [PMID: 34609067 DOI: 10.1002/prp2.778] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Azad AK, Lloyd C, Sadee W, Schlesinger LS. Challenges of Immune Response Diversity in the Human Population Concerning New Tuberculosis Diagnostics, Therapies, and Vaccines. Front Cell Infect Microbiol 2020;10:139. [PMID: 32322562 DOI: 10.3389/fcimb.2020.00139] [Reference Citation Analysis]
25 Oster P, Vaillant L, Mcmillan B, Velin D. The Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection. Front Immunol 2022;13:899161. [DOI: 10.3389/fimmu.2022.899161] [Reference Citation Analysis]
26 Nicoud MB, Táquez Delgado MA, Sarasola MP, Vidal A, Speisky D, Cremaschi GA, Sterle HA, Medina VA. Impact of histamine H4 receptor deficiency on the modulation of T cells in a murine breast cancer model. Cancer Immunol Immunother 2021;70:233-44. [PMID: 32700092 DOI: 10.1007/s00262-020-02672-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Abu Khalaf S, Dandachi D, Granwehr BP, Rodriguez-Barradas MC. Cancer immunotherapy in adult patients with HIV. J Investig Med 2022:jim-2021-002205. [PMID: 35086858 DOI: 10.1136/jim-2021-002205] [Reference Citation Analysis]
28 Shih P. Revisiting the development of small molecular inhibitors that directly target the signal transducer and activator of transcription 3 (STAT3) domains. Life Sciences 2020;242:117241. [DOI: 10.1016/j.lfs.2019.117241] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
29 Hung LVM, Ngo HT, Van Pham P. Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment. In: Pham PV, editor. Cancer Biology and Advances in Treatment. Cham: Springer International Publishing; 2020. pp. 113-30. [DOI: 10.1007/5584_2020_522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Malogolovkin A, Gasanov N, Egorov A, Weener M, Ivanov R, Karabelsky A. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes. Viruses 2021;13:1271. [PMID: 34209981 DOI: 10.3390/v13071271] [Reference Citation Analysis]
31 Filippi L, Nervi C, Proietti I, Pirisino R, Potenza C, Martelli O, Equitani F, Bagni O. Molecular imaging in immuno-oncology: current status and translational perspectives. Expert Rev Mol Diagn 2020;20:1199-211. [PMID: 33215963 DOI: 10.1080/14737159.2020.1854090] [Reference Citation Analysis]
32 Hays E, Bonavida B. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resist Updat 2019;43:10-28. [PMID: 31005030 DOI: 10.1016/j.drup.2019.04.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
33 Malla WA, Arora R, Khan RIN, Mahajan S, Tiwari AK. Apoptin as a Tumor-Specific Therapeutic Agent: Current Perspective on Mechanism of Action and Delivery Systems. Front Cell Dev Biol 2020;8:524. [PMID: 32671070 DOI: 10.3389/fcell.2020.00524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
34 Augustus E, Zwaenepoel K, Siozopoulou V, Raskin J, Jordaens S, Baggerman G, Sorber L, Roeyen G, Peeters M, Pauwels P. Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy-The Role of Liquid Biopsy in Unraveling the Puzzle. Cancers (Basel) 2021;13:1675. [PMID: 33918147 DOI: 10.3390/cancers13071675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Deligiorgi MV, Panayiotidis MI, Trafalis DT. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. Immunotherapy 2020;12:481-510. [PMID: 32345074 DOI: 10.2217/imt-2019-0132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Timin AS, Postovalova AS, Karpov TE, Antuganov D, Bukreeva AS, Akhmetova DR, Rogova AS, Muslimov AR, Rodimova SA, Kuznetsova DS, Zyuzin MV. Calcium carbonate carriers for combined chemo- and radionuclide therapy of metastatic lung cancer. J Control Release 2022:S0168-3659(22)00095-5. [PMID: 35181413 DOI: 10.1016/j.jconrel.2022.02.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Hoo WPY, Siak PY, In LLA. Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. Curr Top Med Chem 2019;19:2158-75. [PMID: 31483231 DOI: 10.2174/1568026619666190904163524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Ippolito D, Maino C, Ragusi M, Porta M, Gandola D, Franzesi CT, Giandola TP, Sironi S. Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy. World J Clin Oncol 2021; 12(5): 323-334 [PMID: 34131564 DOI: 10.5306/wjco.v12.i5.323] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Shahid RK, Ahmed S, Le D, Yadav S. Diabetes and Cancer: Risk, Challenges, Management and Outcomes. Cancers (Basel) 2021;13:5735. [PMID: 34830886 DOI: 10.3390/cancers13225735] [Reference Citation Analysis]
40 Lu F, Ma XJ, Jin WL, Luo Y, Li X. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges. Front Immunol 2021;12:690565. [PMID: 34054880 DOI: 10.3389/fimmu.2021.690565] [Reference Citation Analysis]
41 Hadfield MJ, Helsing R, Grant-Kels JM. Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapies. Melanoma Res 2020;30:429-32. [PMID: 32590412 DOI: 10.1097/CMR.0000000000000679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Bhatia K, Bhumika, Das A. Combinatorial drug therapy in cancer - New insights. Life Sci 2020;258:118134. [PMID: 32717272 DOI: 10.1016/j.lfs.2020.118134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
43 Szczyrek M, Bitkowska P, Chunowski P, Czuchryta P, Krawczyk P, Milanowski J. Diet, Microbiome, and Cancer Immunotherapy-A Comprehensive Review. Nutrients 2021;13:2217. [PMID: 34203292 DOI: 10.3390/nu13072217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Vackova J, Piatakova A, Polakova I, Smahel M. Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade. Int J Mol Sci 2020;21:E1806. [PMID: 32155707 DOI: 10.3390/ijms21051806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Juvale IIA, Hassan Z, Has ATC. The Emerging Roles of π Subunit-Containing GABAA Receptors in Different Cancers. Int J Med Sci 2021;18:3851-60. [PMID: 34790061 DOI: 10.7150/ijms.60928] [Reference Citation Analysis]
46 Singh P, Yadav M, Niveria K, Verma AK. Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment. Exploration of Medicine. [DOI: 10.37349/emed.2022.00072] [Reference Citation Analysis]
47 Li J, Wu J, Zhao Z, Zhang Q, Shao J, Wang C, Qiu Z, Li W. Artificial intelligence-assisted decision making for prognosis and drug efficacy prediction in lung cancer patients: a narrative review. J Thorac Dis 2021;13:7021-33. [PMID: 35070384 DOI: 10.21037/jtd-21-864] [Reference Citation Analysis]
48 Poorebrahim M, Sadeghi S, Fakhr E, Abazari MF, Poortahmasebi V, Kheirollahi A, Askari H, Rajabzadeh A, Rastegarpanah M, Linē A, Cid-Arregui A. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. Crit Rev Clin Lab Sci 2019;56:393-419. [PMID: 31314617 DOI: 10.1080/10408363.2019.1633512] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
49 Lan H, Zhang W, Jin K, Liu Y, Wang Z. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective. Drug Deliv 2020;27:1248-62. [PMID: 32865029 DOI: 10.1080/10717544.2020.1809559] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
50 Ma R, Yi B, Riker AI, Xi Y. Metformin and cancer immunity. Acta Pharmacol Sin 2020;41:1403-9. [PMID: 32868904 DOI: 10.1038/s41401-020-00508-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
51 St-Pierre F, Bhatia S, Chandra S. Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies. Cancers (Basel) 2021;13:1988. [PMID: 33924213 DOI: 10.3390/cancers13081988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
52 Li D, Li X, Zhou WL, Huang Y, Liang X, Jiang L, Yang X, Sun J, Li Z, Han WD, Wang W. Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther 2019;4:35. [PMID: 31637014 DOI: 10.1038/s41392-019-0070-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 20.3] [Reference Citation Analysis]